Oral liquid formulation of levothyroxine is stable in breakfast beverages and may improve thyroid patient compliance

Pharmaceutics

Volumn 5, Issue 4, 2013, Pages 621-633

  Bernareggi, Alberto ^a   Grata, Elia ^b   Pinorini, Maria Teresa ^b   Conti, Ario ^b  

^a Institut Biochimique SA (IBSA)   (Switzerland)

^b Alpine Foundation for Life Sciences (AFLS)   (Switzerland)

Author keywords

Bioavailability; Coffee; LC MS MS; Levothyroxine; Liquid formulation; Milk; Orange juice; Stability; T4; Tea

Indexed keywords

LEVOTHYROXINE SODIUM;

ARTICLE; BEVERAGE; COFFEE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG SENSITIVITY; DRUG STABILITY; FOOD INTAKE; HUMAN; IN VIVO STUDY; INCUBATION TIME; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MILK; MORNING DOSAGE; ORANGE JUICE; PATIENT COMPLIANCE; ROOM TEMPERATURE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TEA; THYROID FUNCTION;

EID: 84890526618     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics5040621     Document Type: Article

References (18)

1. Mandel, S.J.; Brent, G.A.; Larsen, P.R. Levothyroxine therapy in patients with thyroid disease. Ann. Intern. Med. 1993, 119, 492-502.
2. Wenzel, K.W.; Kirschsieper, H.E. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977, 26, 1-8.
3. Lamson, M.J.; Pamplin, C.L.; Rolleri, R.L.; Klein, I. Quantitation of a substantial reduction in levothyroxine (T4) absorption by food. Thyroid 2004, 14, 876.
4. Bach-Huynh, T.G.; Nayak, B.; Loh, J.; Soldin, S.; Jonklaas, J. Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 2009, 94, 3905-3912.
5. Perez, C.L.S.; Araki, F.S.; Graf, H.; de Carvalho, G.A. Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid 2013, 23, 779-784.
6. Seechurn, S.; Sharma, S.; Oyibo, S. Administration of levothyroxine 45-60 min before breakfast improves biochemical availability as evidenced by reduced thyrotropin Levels. Open J. Endocr. Metab. Dis. 2012, 2, 36-39.
7. Bell, D.S.H.; Ovalle, F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr. Pract. 2001, 7, 193-194.
8. Benvenga, S.; Bartolone, L.; Squadrito, S.; Lo Giudice, F.; Trimarchi, F. Delayed intestinal absorption of levothyroxine. Thyroid 1995, 5, 249-253.
9. Benvenga, S.; Bartolone, L.; Pappalardo, M.A.; Russo, A.; Lapa, D.; Giorgianni, G.; Saraceno, G.; Trimarchi, F. Altered intestinal absorption of L-Thyroxine caused by coffee. Thyroid 2008, 18, 293-301.
10. Lilja, J.J.; Laitinen, K.; Neuvonen, P.J. Effects of grapefruit juice on the absorption of levothyroxine. Br. J. Clin. Pharmacol. 2005, 60, 337-341.
11. Benvenga, S.; Ducharme, M.P. Comparison of the intestinal absorption of levothyroxine (LT4): Tablet vs. soft gel capsule formulation. Endocr. Rev. 2011, 32, P3-625.
12. Vita, R.; Saraceno, G.; Trimarchi, F.; Benvenga, S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 2013, 43, 154-160.
13. Saraceno, G.; Vita, R.; Trimarchi, F.; Benvenga, F. Two novel formulations of L-T4 (oral solution and soft gel capsule) are refractory to the coffee-induced intestinal malabsorption of tablet L-T4. Eur. Thyroid J. 2013, 2, P132-P145.
14. Vita, T.; Benvenga, S. Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor: A problem that was solved by switching to L-T4 in soft gel capsule. Endocr. Pract. 2013, 18, 1-11.
15. Pirola, I.; Formenti, A.M.; Gandossi, E.; Mittempergher, F.; Casella, C.; Agosti, B.; Cappelli, C. Oral liquid L-thyroxine (L-T4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes. Surg. 2013, 23, 1493-1496.
16. Cappelli, C.; Pirola, I.; Gandossi, E.; Formenti, A.M.; Castellano, M. Oral liquid levothyroxine treatment at breakfast: A mistake? Eur. J. Endocrinol. 2013, 170, 95-99.
17. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation; Food and Drug Administration: Rockville, MD, USA, 2001.
18. Matuszewski, B.K.; Constanzer, M.L.; Chavez-Eng, C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019-3030.